Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)
Conditions
Secondary Hyperparathyroidism
Conditions: official terms
Hyperparathyroidism - Hyperparathyroidism, Secondary - Kidney Diseases - Neoplasm Metastasis - Renal Insufficiency, Chronic
Conditions: Keywords
Cinacalcet, PK, Secondary Hyperparathyroidism, Paediatric, Chronic Kidney Disease, Dialysis
Study Type
Interventional
Study Phase
Phase 2/Phase 3
Study Design
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Cinacalcet HCl
Type: Drug
Overall Status
Recruiting
Summary
Twelve-month, multicenter, intra-subject controlled (retrospective-prospective), open-label, active-treatment study to evaluate the dose-response and pharmacokinetics (PK) of cinacalcet HCl for the treatment of Secondary Hyperparathyroidism (SHPT) in paediatric subjects with chronic kidney disease (CKD) on dialysis, followed by 12-month study extension.
Detailed Description
This multicenter, intra-subject controlled, open-label, active-treatment study will assess in children affected by Secondary Hyperparathyroidism, aged 2-18 years on chronic dialysis not responsive to standard of care (SoC) therapy, the response after 6-month cinacalcet compared intra-subject to SoC alone at screening visit 6 months prior to cinacalcet start. Secondary objectives are to evaluate effects on growth over 18 months and PK profile. At baseline children have PTH levels>300 pg/mL, plasma P<6 mg/dL, and Ca 8.4-10.5 mg/dL, or Ca x P product>60 not responsive to SoC. Initial dosing of cinacalcet will be 0.5-0.75 mg/Kg per os OD to be adjusted up to a max of 180mg OD for target PTH values<180 pg/mL in absence of hypocalcemia. Thirty children will be enrolled at 12 centres participating in a national paediatric dialysis registry, corresponding to an α=0.05 and a power of 80% using the McNemar test, with an expected % of responders to cinacalcet or SoC of 40% or 5% respectively, with a drop-out rate of 15. Primary study endpoint (EP) will be the % of children who will have a reduction from baseline >25% in mean PTH levels during the 6-mo efficacy-assessment period. Among secondary EPs over 18 mos will be the % of patients with mean PTH levels<300 pg/mL; the % change in PTH, Ca, P values, and the Ca x P product; PK profile (or population profile by age) and its correlation with PTH and testosterone levels; auxological indices and growth velocity; % of children with treatment-emergent adverse events and lab abnormalities; retention on treatment and reasons of treatment withdrawal. The study will evaluate whether cinacalcet represents a safe and effective therapeutic option for SHPT children.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 18 Years
Minimum Age: 2 Years
Gender: Both
Criteria: Inclusion Criteria:

- Parents'/guardian written informed consent, and child's assent

- Age > 2 and <18 years;

- A dry body weight (BW) >10.49 Kg in males and >9.95 Kg in females, respectively;

- Inpatient or outpatient status at the time of enrolment;

- Males or females. Female subjects sexually active must be neither pregnant nor breastfeeding, and must lack childbearing potential from screening visit to the end of the safety follow-up

- On stable hemodialysis (HD) or peritoneal dialysis (PD) for their CKD for at least one month before entering the 6-month pre-treatment period;

- Plasma iPTH levels > 300 pg/mL, AND

- Plasma Ca levels > 9.4 mg/dL (with normal serum albumin level), AND

- Plasma P levels <6.5 mg/dL in patients younger than 6 years, or <6.0mg/dL in older patients, OR

- Ca x P product > 60;

- Records' availability for the following parameters 6 months prior to study entry: demographic information, physical examination, height and dry weight, auxological/anthropometric indices, blood pressure values, Kt/V urea, plasma iPTH, calcium, phosphorus, and alkaline phosphatise levels, blood pH and bicarbonate, serum creatinine/urea, C reactive protein (CRP) levels, liver function tests, blood count, blood 25(OH) vitamin D3 level.

Exclusion Criteria:

- The following laboratory values: Hb<9.0 g/dL, WBC<2000/mm3 (2x109/L), platelets <150,000/mm3 (150x109/L) only in subjects who are otherwise eligible for PK/PD assessments; abnormal liver function, defined by a total bilirubin ≥2 times the upper limit of normal values, ASAT, ALAT, γ-GT levels ≥2 times the ULN values.

- Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study.

- History of malignancy (active malignancy, or off therapy since less than 1 year)

- History of diseases causing hypercalcemia

- Chronic inflammatory diseases (C-Reactive Protein-CRP >2 times the upper limit of normal values) requiring a concomitant corticosteroid or immunosuppressive therapy

- History of infectious diseases (including opportunistic infections) within 4 weeks prior to study entry

- Evidence as assessed by the Investigator of active or latent bacterial, viral or fungal infections at the time of potential enrollment, including subjects with evidence of HIV infection.

- Hepatitis-B surface antigen-positive subjects only in subjects who are otherwise eligible for PK/PD assessments

- Hepatitis C antibody-positive subjects who are also PCR-positive or RIBA positive only in subjects who are otherwise eligible for PK/PD assessments

- Use of recombinant human growth hormone therapy

- Use of drugs that interact with cinacalcet disposition

- Previous use of cinacalcet
Locations
U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII
Bari, Italy
Status: Active, not recruiting
U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini
Genoa, Italy
Status: Recruiting
Contact: Enrico E Verrina, MD - +390105636276 - enricoverrina@ospedale-gaslini.ge.it
U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi
Milan, Italy
Status: Active, not recruiting
U.O. Nefrologia e Dialisi - Ospedale Santobono
Naples, Italy
Status: Active, not recruiting
U.O. Nefrologia e Dialisi - Ospedale Bambino Gesù
Rome, Italy
Status: Active, not recruiting
Start Date
March 2010
Completion Date
December 2013
Sponsors
ENRICO VERRINA
Source
Istituto Giannina Gaslini
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page